Notably, during simvastatin-induced cell death through c-Jun N-terminal kinase (JNK) activation in DU145 human prostate cancer cells, TXNDC5 exhibited an opposite effect to vimentin, RAB1B, HMGCR, HNRNPK, NDRG1, and IDI1, as it was downregulated despite an increase in its molecular weight, suggesting significant post-translational modification [50]. The gene discussed is TXNDC5; the disease is prostate cancer.